Financial Performance - The company's operating revenue for 2023 was CNY 651,436,758.68, representing a 3.84% increase compared to CNY 627,364,047.52 in 2022[23]. - The net profit attributable to shareholders for 2023 was CNY 158,979,232.75, a 20.16% increase from CNY 132,304,592.95 in 2022[23]. - The net cash flow from operating activities surged by 213.19% to CNY 259,459,970.22 in 2023, compared to CNY 82,845,438.18 in 2022[23]. - Total revenue for 2023 reached ¥651,436,758.68, representing a year-on-year increase of 3.84% compared to ¥627,364,047.52 in 2022[62]. - Revenue from pharmaceutical intermediates was ¥643,848,065.01, accounting for 98.84% of total revenue, with a year-on-year growth of 3.64%[62]. - The company reported a total of CNY 14,822,675.02 in non-recurring gains for 2023, compared to CNY 2,599,812.76 in 2022[29]. - The company reported a total revenue of 9999 million for the year 2022, indicating a stable performance[187]. - The company reported a significant increase in revenue for the fiscal year 2022, reaching 9999 million, reflecting a strong performance compared to the previous year[189]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 4 RMB per 10 shares to all shareholders, based on a total of 200,040,000 shares[3]. - The profit distribution plan for 2022 was approved, with a cash dividend of 5 RMB per 10 shares (including tax) and a capital reserve conversion of 5 shares for every 10 shares held[150]. - The company reported a profit distribution plan of 4 RMB per 10 shares and a capital reserve conversion of 4 shares per 10 shares[151]. - The company aims to enhance investor returns through its clear profit distribution and capital reserve conversion plans[151]. - The company plans to prioritize cash dividends, distributing at least 10% of the distributable profits in the absence of major investment plans or significant cash expenditures[185]. - In the next three years, the company aims to maintain a minimum cash dividend ratio of 20% due to its growth stage and significant capital expenditure plans[186]. - The company will ensure that cash dividends are distributed within two months after the shareholder meeting decision[186]. Research and Development - The company has established long-term collaborations with universities and research institutions to strengthen its R&D capabilities[42]. - The company is committed to innovation, with a focus on developing new drugs and improving existing products in response to market demands[39]. - The company has established R&D platforms in Beijing and Zhengzhou to accelerate technological innovation and project development[47]. - R&D expenses increased by 73.19% to ¥51,962,017.16, driven by higher investments in raw materials and formulations[69]. - The number of R&D personnel increased to 240 in 2023, up 57.89% from 152 in 2022, with R&D personnel accounting for 23.76% of the total workforce[72]. - R&D investment reached ¥51,962,017.16 in 2023, representing 7.98% of operating revenue, a significant increase from 4.78% in 2022[73]. - The company is investing in R&D, with a budget increase of 25% to enhance product innovation and technology development[132]. Market and Sales Strategy - The company is expanding its market presence through both direct sales and partnerships with trading companies for international clients[46]. - Domestic sales contributed ¥641,158,923.48, up 4.89% year-on-year, while international sales dropped by 36.15% to ¥10,277,835.20[62]. - The company is actively expanding its integrated development strategy of intermediates and raw materials, which is expected to enhance product value and drive revenue growth[50]. - The company is considering strategic acquisitions to bolster its product portfolio, with a target of completing at least one acquisition by the end of the fiscal year[132]. - The company plans to enhance its digital marketing strategy, allocating an additional 10% of its budget to online advertising[132]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[134]. Compliance and Governance - The company emphasizes that forward-looking statements regarding operational plans and future strategies do not constitute substantial commitments or profit forecasts to investors[3]. - The company maintains compliance with corporate governance regulations and has a structured board with independent directors to ensure sound decision-making[109]. - The company has established a transparent and effective performance evaluation and incentive mechanism for its management team[112]. - The company has not reported any significant changes in its board of directors or senior management apart from the aforementioned appointments and resignations[124]. - The company will ensure that any commitments made are in compliance with the latest regulations from the China Securities Regulatory Commission[184]. - The company has established strict compliance measures regarding the management of raised funds and related party transactions to protect shareholder interests[189]. Environmental and Social Responsibility - The company has established a clean production leadership group and invested continuously in environmental facilities to ensure compliance with waste discharge standards[100]. - The company has received the "Waste-Free Factory" honor from Xuchang City, reinforcing its commitment to waste management and resource utilization[166]. - The company has implemented a comprehensive environmental monitoring plan, including automatic and manual monitoring methods, to ensure compliance with pollution discharge standards[168]. - The company has committed to enhancing its core competitiveness through innovation and product transformation in response to market-oriented strategies[100]. - The company has actively participated in social responsibility initiatives, donating a total of 144,000 yuan to various charitable activities in 2023[176]. Risk Management - The company has detailed potential risk factors and countermeasures in its report, urging investors to be aware of investment risks[3]. - The company faces risks related to its core product, L-α-hydroxyphenylglycine, which contributes over 80% to its main business revenue, making it vulnerable to demand fluctuations[99]. - The company is facing potential risks from national healthcare policies that may pressure drug prices downward, impacting future profitability[100]. - The company emphasizes a dual prevention system for safety management and has implemented a PDCA cycle management model to mitigate safety risks[100]. Investment and Fundraising - The company raised a total of ¥900,720,000 through its initial public offering, with a net amount of ¥815,565,800 after deducting issuance costs[85]. - The company plans to invest ¥100,000,000 of its excess raised funds into the construction of an intelligent specialty raw material pharmaceutical supply chain project[89]. - The total investment amount for the reporting period reached ¥3,789,714,975.79, a significant increase of 389.41% compared to ¥774,342,722.37 in the same period last year[81]. - The company has not engaged in any securities or derivative investments during the reporting period[82][83]. Employee and Management - The company has a total of 240 technical personnel, accounting for 23.76% of its total workforce, indicating a strong focus on R&D capabilities[54]. - The management team has over ten years of experience in the industry, providing deep insights into market dynamics and enhancing strategic decision-making[59]. - The company has established a competitive salary and benefits system to enhance employee motivation and performance, aligning with the principles of fairness and contribution-based distribution[148].
新天地(301277) - 2023 Q4 - 年度财报